RT Journal Article
SR Electronic
T1 Ornithine Decarboxylase (<em>ODC1</em>) gene variant (rs2302615) is associated with gastric cancer independently of <em>Helicobacter pylori</em> CagA serostatus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21254467
DO 10.1101/2021.04.13.21254467
A1 Anna K Miller
A1 Gloria Tavera
A1 Ricardo L Dominguez
A1 M Constanza Camargo
A1 Tim Waterboer
A1 Keith T Wilson
A1 Scott M Williams
A1 Douglas R Morgan
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2021.04.13.21254467.abstract
AB The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO). Our population-based, case-control study included 1366 individuals (664 gastric cancer cases and 702 controls) from Western Honduras, a high incidence region of Latin America. CagA seropositivity was strongly associated with cancer (OR = 3.6; 95% CI: 2.6, 5.1). The ODC1 variant rs2302615 was associated with gastric cancer (OR = 1.36; p = 0.018) in a model adjusted for age, sex, and CagA serostatus. Two additional single nucleotide polymorphisms (SNPs) in CASP1 (rs530537) and TLR4 (rs1927914) genes were also associated with gastric cancer. The ODC1 SNP association with gastric cancer was stronger in individuals who carried the TT genotype at the associating TLR4 polymorphism, rs1927914 (OR = 1.77; p = 1.85 × 10−3). In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the risk allele, C, at rs2302615.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by the U.S. National Cancer Institute P01CA028842 (DRM, KTW, SMW), R01CA190612 (DRM, KTW), K07 CA125588 (DRM), PAR-15-155 (DRM), P30CA068485 (DRM, KTW), P01CA116087 (KTW), Veterans Affairs Merit2 Review grant I01CX002171 (KTW), Department of Defense grant W81XWH-18-1-0301 (KTW), and National Library of Medicine 1R01LM010098 (SMW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB for this study is from Vanderbilt University and was approved in 2012 with the study number #120241. This study is exempt from federal regulation because of exemption #4 as it only kept limited information about the patients, including their medical record number.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis data will be publicly available 6 months after formal publication.